Sichuan Huiyu Pharmaceutical Co., Ltd. carries a market capitalization of 8.26B, placing it among publicly traded companies globally. Its enterprise value stands at 2.59B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.26B |
| Enterprise Value | 2.59B |
Sichuan Huiyu Pharmaceutical Co., Ltd. currently has 423.60M shares outstanding.
| Shares Outstanding | 423.60M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Sichuan Huiyu Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 26.20. The price-to-sales ratio is 4.63, and the price-to-book ratio stands at 4.27.
| PE Ratio | 26.20 |
| PS Ratio | 4.63 |
| PB Ratio | 4.27 |
| P/TBV Ratio | 1.31 |
| P/FCF Ratio | 49.10 |
| P/OCF Ratio | N/A |
On an enterprise value basis, Sichuan Huiyu Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 70.15 and an EV/FCF ratio of 24.37. The EV/Sales ratio of 2.55 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 70.15 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.55 |
| EV / EBITDA | 70.15 |
| EV / EBIT | 70.15 |
| EV / FCF | 24.37 |
Sichuan Huiyu Pharmaceutical Co., Ltd. maintains a current ratio of 2.86, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.79, indicating elevated leverage, while an interest coverage ratio of 3.46 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 2.86 |
| Quick Ratio | 2.45 |
| Debt / Equity | 13.79 |
| Debt / EBITDA | 13.79 |
| Interest Coverage | 3.46 |
Sichuan Huiyu Pharmaceutical Co., Ltd. posts a return on equity of 15.90 and a return on invested capital of 0.85.
| Return on Equity (ROE) | 15.90 |
| Return on Assets (ROA) | 3.76 |
| Return on Invested Capital (ROIC) | 0.85 |
| Return on Capital Employed (ROCE) | 12.03 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.95 |
Over the trailing twelve months, Sichuan Huiyu Pharmaceutical Co., Ltd. has paid 3.26M in income taxes, reflecting an effective tax rate of 1.88.
| Income Tax | 3.26M |
| Effective Tax Rate | 1.88 |
Sichuan Huiyu Pharmaceutical Co., Ltd.'s stock has declined approximately -2.51108% over the past 52 weeks. The 50-day moving average sits at 12.34, while the 200-day moving average is 13.08.
| Beta (5Y) | N/A |
| 52-Week Price Change | -2.51108% |
| 50-Day Moving Average | 12.34 |
| 200-Day Moving Average | 13.08 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Sichuan Huiyu Pharmaceutical Co., Ltd. generated 1.02B in revenue and converted that into 179.46M in net income, yielding earnings per share of 0.40. EBITDA reached 36.92M, while operating income came in at 36.92M.
| Revenue | 1.02B |
| Gross Profit | 834.75M |
| Operating Income | 36.92M |
| Pretax Income | 173.36M |
| Net Income | 179.46M |
| EBITDA | 36.92M |
| EBIT | 36.92M |
| Earnings Per Share (EPS) | 0.40 |
Sichuan Huiyu Pharmaceutical Co., Ltd. holds 2.61B in cash and equivalents against 509.04M in total debt, resulting in a net debt position of -1.58B. Total book value stands at 1.10B, with working capital of 1.98B providing operational flexibility.
| Cash & Cash Equivalents | 2.61B |
| Total Debt | 509.04M |
| Net Debt | -1.58B |
| Equity (Book Value) | 1.10B |
| Book Value Per Share | 2.58 |
| Working Capital | 1.98B |
After subtracting -95.77M in capital expenditures, free cash flow totaled -95.77M - equivalent to -0.22 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -95.77M |
| Free Cash Flow | -95.77M |
| FCF Per Share | -0.22 |
Sichuan Huiyu Pharmaceutical Co., Ltd. operates with a gross margin of 82.22, reflecting its pricing power and cost economics. The operating margin of 3.64 and net profit margin of 17.68 provide insight into operational efficiency.
| Gross Margin | 82.22 |
| Operating Margin | 3.64 |
| Pretax Margin | 17.07 |
| Profit Margin | 17.68 |
| EBITDA Margin | 3.64 |
The company's payout ratio of 123.87 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.47 |
| Dividend Yield | N/A |
| Payout Ratio | 123.87 |
| Shareholder Yield | 4.31 |
| FCF Yield | 2.04 |
Sichuan Huiyu Pharmaceutical Co., Ltd.'s most recent stock split took place on June 17, 2026 with a 25:37 split ratio.
| Last Split Date | 6/17/2026 |
| Split Ratio | 25:37 |
Sichuan Huiyu Pharmaceutical Co., Ltd. posts an Altman Z-Score of 3.41, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.41 |